Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes - PubMed (original) (raw)
Observational Study
. 2017 Jun;19(6):831-841.
doi: 10.1111/dom.12889. Epub 2017 Mar 16.
Affiliations
- PMID: 28116795
- PMCID: PMC5485030
- DOI: 10.1111/dom.12889
Observational Study
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
Thomas Nyström et al. Diabetes Obes Metab. 2017 Jun.
Abstract
Aims: To investigate the association of novel oral glucose-lowering drugs (GLDs), compared with that of insulin, with risk of all-cause mortality, cardiovascular disease (CVD) and severe hypoglycaemia.
Methods: During 2013 to 2014 all patients with type 2 diabetes in Sweden identified as new users of novel oral GLDs, either dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT2) inhibitors (only dapagliflozin available in Sweden during the study period), with those initiating insulin as a comparison group, in the Prescribed Drug Register were included and followed in the Patient and Cause of Death Registers. The novel GLD group and insulin group were matched 1:1 using propensity score. Cox regression models were used to estimate risks.
Results: Of 37 603 patients, 21 758 were matched 1:1 to novel GLD vs insulin groups, with median follow-up times of 1.51 years (16 304 patient-years) and 1.53 years (16 306 patient-years), respectively. Treatment with novel GLDs was associated with a 44% (hazard ratio [HR] 0.56 [95% confidence interval {CI} 0.49-0.64]), 15% (HR 0.85 [95% CI 0.73-0.99]) and 74% (0.26 [95% CI 0.12-0.57]) lower risk of all-cause mortality, CVD and hypoglycaemia, respectively, compared with insulin treatment. In separate analyses for the two novel GLDs, dapagliflozin was associated with lower risks of all-cause mortality and CVD (56% [HR 0.44, 95% CI 0.28-0.70] and 49% [HR 0.51, 95% CI 0.30-0.86], respectively), while DPP-4 inhibitor treatment was associated with lower risk of all-cause mortality (41% [HR 0.59, 95% CI 0.51-0.67]), but not with CVD (HR 0.87, 95% CI 0.75-1.01).
Conclusions: Novel oral GLD treatment was associated with lower risk of all-cause mortality, CVD and severe hypoglycaemia compared with insulin treatment. Dapagliflozin was associated with a lower risk of both all-cause mortality and CVD, whereas DPP-4 inhibitor treatment was only associated with lower risk of all-cause mortality.
Keywords: DPP-4 inhibitor; cardiovascular disease; dapagliflozin; hypoglycaemia; pharmaco-epidemiology; type 2 diabetes.
© 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Figures
Figure 1
Patient flow chart.
Figure 2
Kaplan–Meier curves and
HRs
comparing propensity score‐matched novel
GLD
and insulin groups for A, all‐cause mortality; B, fatal and non‐fatal
CVD
; and C, severe hypoglycaemia. [Correction added on 28th April, after first online publication: Supplied Figure 2 was previously incorrect and has been amended in this version]
Figure 3
Kaplan–Meier curves and
HRs
comparing propensity score‐matched dapagliflozin and
DPP
‐4 inhibitors vs insulin groups for A and B, all‐cause mortality; C and D, fatal and non‐fatal
CVD
; and E and F, severe hypoglycaemia.
Similar articles
- Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Eriksson JW, Norhammar A, Bodegard J, Birkeland KI. Persson F, et al. Diabetes Obes Metab. 2018 Feb;20(2):344-351. doi: 10.1111/dom.13077. Epub 2017 Sep 8. Diabetes Obes Metab. 2018. PMID: 28771923 Free PMC article. - Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A. Birkeland KI, et al. Lancet Diabetes Endocrinol. 2017 Sep;5(9):709-717. doi: 10.1016/S2213-8587(17)30258-9. Epub 2017 Aug 3. Lancet Diabetes Endocrinol. 2017. PMID: 28781064 - Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Nyström T, et al. Diabetes Res Clin Pract. 2017 Jan;123:199-208. doi: 10.1016/j.diabres.2016.12.004. Epub 2016 Dec 19. Diabetes Res Clin Pract. 2017. PMID: 28056431 - SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I. Lingvay I. Endocr Pract. 2017 Jul;23(7):831-840. doi: 10.4158/EP161725.RA. Epub 2017 Mar 23. Endocr Pract. 2017. PMID: 28332871 Review.
Cited by
- Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.
Fadini GP, Longato E, Morieri ML, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Fadini GP, et al. Lancet Reg Health Eur. 2024 Feb 1;38:100847. doi: 10.1016/j.lanepe.2024.100847. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38328413 Free PMC article. - Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies.
Li CX, Liu TT, Zhang Q, Xie Q, Geng XH, Man CX, Li JY, Mao XY, Qiao Y, Liu H. Li CX, et al. Front Pharmacol. 2023 Oct 13;14:1275060. doi: 10.3389/fphar.2023.1275060. eCollection 2023. Front Pharmacol. 2023. PMID: 37905204 Free PMC article. - SGLT1: A Potential Drug Target for Cardiovascular Disease.
Zhao M, Li N, Zhou H. Zhao M, et al. Drug Des Devel Ther. 2023 Jul 6;17:2011-2023. doi: 10.2147/DDDT.S418321. eCollection 2023. Drug Des Devel Ther. 2023. PMID: 37435096 Free PMC article. Review. - Efficacy of Dapagliflozin in Southern Europe Across the Spectrum of Characteristics of Type 2 Diabetes: An International Real-World Analysis.
Fadini GP, Morales C, Caballero I, González B, Tentolouris N, Consoli A. Fadini GP, et al. Diabetes Metab Syndr Obes. 2022 Nov 15;15:3533-3541. doi: 10.2147/DMSO.S390075. eCollection 2022. Diabetes Metab Syndr Obes. 2022. PMID: 36411790 Free PMC article. - Impact of diabetes on COVID-19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta-analysis.
Kastora S, Patel M, Carter B, Delibegovic M, Myint PK. Kastora S, et al. Endocrinol Diabetes Metab. 2022 May;5(3):e00338. doi: 10.1002/edm2.338. Epub 2022 Apr 20. Endocrinol Diabetes Metab. 2022. PMID: 35441801 Free PMC article. Review.
References
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient‐centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140‐149. - PubMed
- Russell‐Jones D, Khan R. Insulin‐associated weight gain in diabetes–causes, effects and coping strategies. Diabetes Obes Metab. 2007;9(6):799‐812. - PubMed
- Davis TM, Clifford RM, Davis WA, Fremantle Diabetes Study . Effect of insulin therapy on quality of life in type 2 diabetes mellitus: The Fremantle Diabetes Study. Diabetes Res Clin Pract. 2001;52(1):63‐71. - PubMed
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm–2016 executive summary. Endocr Pract. 2016;22(1):84‐113. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous